Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 5/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | PRKCA | P17252 | 4/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17955795 | 0.86 | PRKCA (0.33) | HCAR2ATMPRKCALMNASERPINE1 | |
| SCHEMBL17955575 | 0.85 | ALDH1A1 (0.32) | HCAR2ATMPRKCATSHRALDH1A1 | |
| SCHEMBL17955634 | 0.83 | PRKCA (0.31) | PRKCA | |
| SCHEMBL17955614 | 0.83 | HCAR2 (0.52) | HCAR2ATMTSHRALDH1A1LMNA | |
| SCHEMBL17955615 | 0.81 | HCAR2 (0.46) | HCAR2ATMTSHRTDP1 | |
| SCHEMBL18475971 | 0.79 | — | — | |
| SCHEMBL17955632 | 0.78 | DRD4 (0.41) | ALDH1A1LMNA | |
| SCHEMBL7780698 | 0.76 | HCAR2 (0.38) | HCAR2ATMPRKCALMNA | |
| SCHEMBL3516782 | 0.76 | HCAR2 (0.38) | HCAR2ATMPRKCALMNA | |
| SCHEMBL17955786 | 0.76 | MEN1 (0.41) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170027898-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | NGUYEN MARK QUANG (US) | 2017-02-02 | — | — | US | disclosed |
| US-9403784-B1 | Fumarate compounds, pharmaceutical compositions thereof, and methods of use | Nguyen, Mark Quang (US) | 2016-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170027898-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, FPGS, APC | HCAR2 290/4885ATM 4406/4885PRKCA 3553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.